Company intelligence / Profile preview
Shanghai Lanque Biomedical Co., Ltd.
Shanghai, Shanghai, Chinacn.rnacure.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has a COVID-19 vaccine (RQ3013-VLP) in Phase 3 clinical trials targeting SARS-CoV-2 S protein, as well as preclinical stage CAR-T cell therapy and COVID-19 mRNA vaccine programs.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- mRNA vaccinesCAR-T cell therapyprophylactic vaccines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Fudan UniversityYunnan Watson Biotechnology Co., Ltd.Walvax Biotechnology Co., Ltd.
Beyond the preview
Go deeper on Shanghai Lanque Biomedical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Lanque Biomedical Co., Ltd..